Market closed

Merus/$MRUS

14:30

16:10

17:45

19:25

21:00

1D1W1MYTD1Y5YMAX

About Merus

Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.

Ticker

$MRUS

Sector

Health Care

Trading on

NASDAQ

Industry

Biotechnology

Headquarters

Utrecht, Netherlands

Employees

201

Website

www.merus.nl

Merus Metrics

BasicAdvanced

$2.8B

-

-$3.98

1.09 -

Price and volume

Market cap

$2.8B

Beta

1.09

52-week high

$61.61

52-week low

$31.27

Average daily volume

662K

Financial strength

Current ratio

8.321

Quick ratio

7.944

Long term debt to equity

1.32

Total debt to equity

1.571

Management effectiveness

Return on assets (TTM)

-21.59%

Return on equity (TTM)

-44.60%

Valuation

Price to revenue (TTM)

69.254

Price to book

3.94

Price to tangible book (TTM)

3.95

Price to free cash flow (TTM)

-15.819

Growth

Revenue change (TTM)

-21.33%

Earnings per share change (TTM)

9.59%

3-year revenue growth (CAGR)

-6.11%

3-year earnings per share growth (CAGR)

20.96%

What the Analysts think about Merus

Analyst Ratings

Analyst ratings (Buy, Hold, Sell) for Merus stock.

Merus Financial Performance

Income Statement

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37B

-39.75%

Net income

$45B

107.52%

Profit margin

37.65%

6.78%

Merus Earnings Performance

Earnings per share (EPS)

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

-

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

-

Merus News

AllArticlesVideos

Merus and Biohaven Announce Collaboration to Co-Develop Three Novel Bispecific ADC Programs

GlobeNewsWire·2 days ago

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

GlobeNewsWire·4 weeks ago

Merus' Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

GlobeNewsWire·1 month ago

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $MRUS

$

Capital at risk

Market closed

Upcoming events

No upcoming events

FAQs

What’s the current market cap for Merus stock?

Merus (MRUS) has a market cap of $2.8B as of January 15, 2025.

What is the P/E ratio for Merus stock?

The price to earnings (P/E) ratio for Merus (MRUS) stock is 0 as of January 15, 2025.

Does Merus stock pay dividends?

No, Merus (MRUS) stock does not pay dividends to its shareholders as of January 15, 2025.

When is the next Merus dividend payment date?

Merus (MRUS) stock does not pay dividends to its shareholders.

What is the beta indicator for Merus?

Merus (MRUS) has a beta rating of 1.09. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.